The novel histone deacetylase inhibitor, AR-42, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells

International Journal of Cancer

Volumn 129, Issue 1, 2011, Pages 204-213

  Zhang, Shuhong ^a   Suvannasankha, Attaya ^a   Crean, Colin D ^a   White, Valerie L ^b   Chen, Ching Shih ^b   Farag, Sherif S ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

apoptosis; cell cycle; multiple myeloma

Indexed keywords

AR 42; CASPASE 3; CASPASE 8; CASPASE 9; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GLYCOPROTEIN GP 130; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 6; LENTIVIRUS VECTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL XL; PROTEIN KINASE B; STAT3 PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BONE MARROW BIOPSY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL LINE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG MECHANISM; ENZYME INHIBITION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; LC 50; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN TARGETING; TRANSCRIPTION INITIATION;

ACETYLATION; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CYTOKINE RECEPTOR GP130; HISTONE DEACETYLASE INHIBITORS; HUMANS; MULTIPLE MYELOMA; PHENYLBUTYRATES; PHOSPHORYLATION; STAT3 TRANSCRIPTION FACTOR;

EID: 79955458507     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25660     Document Type: Article

References (50)

1. Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, Walker R, Crowley J,. Treatment of multiple myeloma. Blood 2004; 103: 20-32. (Pubitemid 38029914)
2. Baumann P, Mandl-Weber S, Volkl A, Adam C, Bumeder I, Oduncu F, Schmidmaier R,. Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells. Mol Cancer Ther 2009; 8: 366-75.
3. Hideshima T, Richardson P, Anderson KC,. Novel therapeutic approaches for multiple myeloma. Immunol Rev 2003; 194: 164-76. (Pubitemid 36886435)
4. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS, Jove R,. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10: 105-15. (Pubitemid 29077388)
5. Buettner R, Mora LB, Jove R,. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002; 8: 945-54. (Pubitemid 35177340)
6. Villar-Garea A, Esteller M,. Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int J Cancer 2004; 112: 171-8. (Pubitemid 39244355)
7. Marsoni S, Damia G, Camboni G,. A work in progress: the clinical development of histone deacetylase inhibitor. Epigenetics 2008; 3: 164-71.
8. Kulp SK, Chen CS, Wang DS, Chen CY, Chen CS,. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. Clin Cancer Res 2006; 12: 5199-206. (Pubitemid 44453349)
9. Lavelle D, Chen YH, Hankewych M, DeSimone J,. Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression. Am J Hematol 2001; 68: 170-8. (Pubitemid 32983205)
10. Kaiser M, Zavrski I, Sterz J, Jakob C, Fleissner C, Kloetzel PM, Sezer O, Heider U,. The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica 2006; 91: 248-51.
11. Maiso P, Carvajal-Vergara X, Ocio EM, Lopez-Perez R, Mateo G, Gutierrez N, Atadja P, Pandiella A, San Miguel JF,. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 2006; 66: 5781-9. (Pubitemid 43927132)
12. Catley L, Weisberg E, Tai YT, Atadja P, Remiszewski S, Hideshima T, Mitsiades N, Shringarpure R, LeBlanc R, Chauhan D, Munshi N, Schlossman R, et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 2003; 102: 2615-22. (Pubitemid 37193603)
13. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan D, Munshi N, Gu X, Bailey C, Joseph M, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 2004; 101: 540-5. (Pubitemid 38084672)
14. Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G, Schlossman R, Chauhan D, Munshi NC, Hideshima T, Richon VM, Marks PA, et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003; 101: 4055-62. (Pubitemid 36857886)
15. Richardson P, Mitsiades C, Colson K, Reilly E, McBride L, Chiao J, Sun L, Ricker J, Rizvi S, Oerth C, Atkins B, Fearen I, et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma 2008; 49: 502-7. (Pubitemid 351298334)
16. Lu Q, Wang DS, Chen CS, Hu YD, Chen CS,. Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem 2005; 48: 5530-5. (Pubitemid 41209250)
17. Catley L, Weisberg E, Tai YT, Atadja P, Remiszewski S, Hideshima T, Mitsiades N, Shringarpure R, LeBlanc R, Chauhan D, Munshi NC, Schlossman R, et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 2003; 102: 2615-22. (Pubitemid 37193603)
18. Shao Y, Gao Z, Marks PA, Jiang X,. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 2004; 101: 18030-5. (Pubitemid 40054069)
19. Cai D, Wang Y, Ottmann OG, Barth PJ, Neubauer A, Burchert A,. FLT3-ITD-, but not BCR/ABL-transformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment. Blood 2006; 107: 2094-7. (Pubitemid 43289394)
20. Amin HM, Saeed S, Alkan S,. Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17). Br J Haematol 2001; 115: 287-97. (Pubitemid 34203490)
21. Doi S, Soda H, Oka M, Tsurutani J, Kitazaki T, Nakamura Y, Fukuda M, Yamada Y, Kamihira S, Kohno S,. The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells. Mol Cancer Ther 2004; 3: 1397-402. (Pubitemid 39562584)
22. Lucas DM, Davis ME, Parthun MR, Mone AP, Kitada S, Cunningham KD, Flax EL, Wickham J, Reed JC, Byrd JC, Grever MR,. The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia 2004; 18: 1207-14. (Pubitemid 39023130)
23. Klein B, Zhang XG, Lu ZY, Bataille R,. Interleukin-6 in human multiple myeloma. Blood 1995; 85: 863-72.
24. Hitzler JK, Martinez-Valdez H, Bergsagel DB, Minden MD, Messner HA,. Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCI-My 1 to 7 established from patients with advanced stage of the disease. Blood 1991; 78: 1996-2004.
25. Muto A, Hori M, Sasaki Y, Saitoh A, Yasuda I, Maekawa T, Uchida T, Asakura K, Nakazato T, Kaneda T, Kizaki M, Ikeda Y, et al. Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor. Mol Cancer Ther 2007; 6: 987-94. (Pubitemid 46554568)
26. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L,. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998; 334 (Pt 2): 297-314. (Pubitemid 28448572)
27. Ogata A, Chauhan D, Teoh G, Treon SP, Urashima M, Schlossman RL, Anderson KC,. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 1997; 159: 2212-21. (Pubitemid 127681011)
28. Hsu JH, Shi Y, Hu L, Fisher M, Franke TF, Lichtenstein A,. Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses. Oncogene 2002; 21: 1391-400. (Pubitemid 34214504)
29. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F,. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003; 374: 1-20. (Pubitemid 37046923)
30. Chen Q, Ray S, Hussein MA, Srkalovic G, Almasan A,. Role of Apo2L/TRAIL and Bcl-2-family proteins in apoptosis of multiple myeloma. Leuk Lymphoma 2003; 44: 1209-14. (Pubitemid 36609115)
31. Kataoka T, Schroter M, Hahne M, Schneider P, Irmler M, Thome M, Froelich CJ, Tschopp J,. FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. J Immunol 1998; 161: 3936-42. (Pubitemid 28468969)
32. Perez LE, Parquet N, Shain K, Nimmanapalli R, Alsina M, Anasetti C, Dalton W,. Bone marrow stroma confers resistance to Apo2 ligand/TRAIL in multiple myeloma in part by regulating c-FLIP. J Immunol 2008; 180: 1545-55.
33. Golay J, Cuppini L, Leoni F, Mico C, Barbui V, Domenghini M, Lombardi L, Neri A, Barbui AM, Salvi A, Pozzi P, Porro G, et al. The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia 2007; 21: 1892-900. (Pubitemid 47299961)
34. Wong IH, Ng MH, Lee JC, Lo KW, Chung YF, Huang DP,. Transcriptional silencing of the p16 gene in human myeloma-derived cell lines by hypermethylation. Br J Haematol 1998; 103: 168-75. (Pubitemid 28470815)
35. Hu Y, Benedict MA, Wu D, Inohara N, Nunez G,. Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc Natl Acad Sci USA 1998; 95: 4386-91.
36. Vander Heiden MG, Li XX, Gottleib E, Hill RB, Thompson CB, Colombini M,. Bcl-xL promotes the open configuration of the voltage-dependent anion channel and metabolite passage through the outer mitochondrial membrane. J Biol Chem 2001; 276: 19414-9.
37. Fandy TE, Shankar S, Ross DD, Sausville E, Srivastava RK,. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 2005; 7: 646-57. (Pubitemid 41099418)
38. Kataoka T,. The caspase-8 modulator c-FLIP. Crit Rev Immunol 2005; 25: 31-58. (Pubitemid 40733355)
39. Munshi NC, Hideshima T, Carrasco D, Shammas M, Auclair D, Davies F, Mitsiades N, Mitsiades C, Kim RS, Li C, Rajkumar SV, Fonseca R, et al. Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood 2004; 103: 1799-806. (Pubitemid 38268976)
40. Suvannasankha A, Crean CD, Shanmugam R, Farag SS, Abonour R, Boswell HS, Nakshatri H,. Antimyeloma effects of a sesquiterpene lactone parthenolide. Clin Cancer Res 2008; 14: 1814-22. (Pubitemid 351469468)
41. Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA, Holloway AJ, Johnstone RW,. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005; 102: 3697-702. (Pubitemid 40354674)
42. Valentini A, Gravina P, Federici G, Bernardini S,. Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells. Cancer Biol Ther 2007; 6: 185-91. (Pubitemid 46641621)
43. Gui CY, Ngo L, Xu WS, Richon VM, Marks PA,. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 2004; 101: 1241-6. (Pubitemid 38182673)
44. Lavelle D, Chen YH, Hankewych M, DeSimone J,. Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression. Am J Hematol 2001; 68: 170-8. (Pubitemid 32983205)
45. Deane NG, Parker MA, Beauchamp RD,. Cell proliferation: a matter of time and place. Surgery 2005; 138: 1-7. (Pubitemid 40933765)
46. Bruno B, Giaccone L, Rotta M, Anderson K, Boccadoro M,. Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside. Leukemia 2005; 19: 1729-38. (Pubitemid 41486149)
47. Blanchard F, Wang Y, Kinzie E, Duplomb L, Godard A, Baumann H,. Oncostatin M regulates the synthesis and turnover of gp130, leukemia inhibitory factor receptor alpha, and oncostatin M receptor beta by distinct mechanisms. J Biol Chem 2001; 276: 47038-45.
48. Graf D, Haselow K, Munks I, Bode JG, Haussinger D,. Caspase-mediated cleavage of the signal-transducing IL-6 receptor subunit gp130. Arch Biochem Biophys 2008; 477: 330-8.
49. Amit-Vazina M, Shishodia S, Harris D, Van Q, Wang M, Weber D, Alexanian R, Talpaz M, Aggarwal BB, Estrov Z,. Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. Br J Cancer 2005; 93: 70-80. (Pubitemid 41076255)
50. Yu H, Jove R,. The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 2004; 4: 97-105. (Pubitemid 38198738)